{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:55:00Z","timestamp":1789512900704,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T00:00:00Z","timestamp":1473379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Radius Health, Inc."}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2003<\/jats:title>\n                  <jats:p>Abaloparatide-SC is a novel 34\u2013amino acid peptide created to be a potent and selective activator of the parathyroid hormone receptor type 1 (PTHR1) signaling pathway. In the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) Phase 3 trial (NCT01343004), abaloparatide reduced new morphometric vertebral fractures by 86% compared with placebo (p\u2009&amp;lt;\u20090.001) and nonvertebral fractures by 43% (p\u2009=\u20090.049) in postmenopausal women with osteoporosis. Abaloparatide-SC increased bone mineral density (BMD) 3.4% at the total hip, 2.9% at the femoral neck, and 9.2% at the lumbar spine at 18 months (all p\u2009&amp;lt;\u20090.001 versus placebo). The analysis reported here was designed to evaluate whether fracture risk reductions and BMD accrual were consistent across different levels of baseline risk. Risk factor subgroups were predefined categorically for BMD T-score of the lumbar spine, total hip, and femoral neck (\u2264\u20132.5 versus &amp;gt;\u20132.5 and \u2264\u20133.0 versus &amp;gt;\u20133.0), history of nonvertebral fracture (yes versus no), prevalent vertebral fracture (yes versus no), and age (&amp;lt;65 versus 65 to &amp;lt;75 versus \u226575 years) at baseline. Forest plots show that there were no clinically meaningful interactions between any of the baseline risk factors and the treatment effect of abaloparatide-SC on new morphometric vertebral fractures, nonvertebral fractures, or BMD increases. Abaloparatide provides protection against fractures consistently across a wide variety of ages and baseline risks, including those with and without prior fractures, and it has potential utility for a broad group of postmenopausal women with osteoporosis. \u00a9 2016 American Society for Bone and Mineral Research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/jbmr.2991","type":"journal-article","created":{"date-parts":[[2016,9,9]],"date-time":"2016-09-09T21:21:55Z","timestamp":1473456115000},"page":"17-23","source":"Crossref","is-referenced-by-count":83,"title":["Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors"],"prefix":"10.1093","volume":"32","author":[{"given":"Felicia","family":"Cosman","sequence":"first","affiliation":[{"name":"Clinical Research CenterHelen Hayes HospitalWest HaverstrawNYUSA"},{"name":"Columbia UniversityNew YorkNYUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Hattersley","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.WalthamMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-yi","family":"Hu","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.WalthamMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory C","family":"Williams","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.WalthamMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine A","family":"Fitzpatrick","sequence":"additional","affiliation":[{"name":"Radius Health, Inc.WalthamMAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis M","family":"Black","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and BiostatisticsUniversity of CaliforniaSan FranciscoSan Francisco, CAUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2016,9,9]]},"reference":[{"issue":"1","key":"2024021014264889600_jbmr2991-bib-0001","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"7","key":"2024021014264889600_jbmr2991-bib-0002","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"2024021014264889600_jbmr2991-bib-0003","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1001\/jama.285.3.320","article-title":"Risk of new vertebral fracture in the year following a fracture","volume":"285","author":"Lindsay","year":"2001","journal-title":"JAMA"},{"issue":"11","key":"2024021014264889600_jbmr2991-bib-0004","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00198-004-1627-0","article-title":"An estimate of the worldwide prevalence, mortality and disability associated with hip fracture","volume":"15","author":"Johnell","year":"2004","journal-title":"Osteoporos Int"},{"issue":"10","key":"2024021014264889600_jbmr2991-bib-0005","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1359\/jbmr.060711","article-title":"Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture","volume":"21","author":"Schousboe","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2024021014264889600_jbmr2991-bib-0006","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.297.4.387","article-title":"Risk of subsequent fracture after low-trauma fracture in men and women","volume":"297","author":"Center","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"2024021014264889600_jbmr2991-bib-0007","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2106\/JBJS.G.01529","article-title":"Proximal humeral fracture as a risk factor for subsequent hip fractures","volume":"91","author":"Clinton","year":"2009","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"2024021014264889600_jbmr2991-bib-0008","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1359\/jbmr.090207","article-title":"Hip fracture patients at risk of second hip fracture: a nationwide population-based cohort study of 169, 145 cases during 1977-2001","volume":"24","author":"Ryg","year":"2009","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2024021014264889600_jbmr2991-bib-0009","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/jbmr.35","article-title":"Manitoba Bone Density Program. Time since prior fracture is a risk modifier for 10-year osteoporotic fractures","volume":"25","author":"Giangregorio","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"3","key":"2024021014264889600_jbmr2991-bib-0010","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11914-010-0023-2","article-title":"Timing of subsequent fractures after an initial fracture","volume":"8","author":"van Geel","year":"2010","journal-title":"Curr Osteoporos Rep"},{"issue":"12","key":"2024021014264889600_jbmr2991-bib-0011","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1210\/jc.2014-1971","article-title":"Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment","volume":"99","author":"Cosman","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"2024021014264889600_jbmr2991-bib-0012","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1001\/jama.298.23.2761","article-title":"Long-term risk of incident vertebral fractures","volume":"298","author":"Cauley","year":"2007","journal-title":"JAMA"},{"issue":"5","key":"2024021014264889600_jbmr2991-bib-0013","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"issue":"24","key":"2024021014264889600_jbmr2991-bib-0014","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"1","key":"2024021014264889600_jbmr2991-bib-0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/jbmr.536","article-title":"Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis","volume":"27","author":"McClung","year":"2012","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2024021014264889600_jbmr2991-bib-0016","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1002\/jbmr.2283","article-title":"Subgroup variations in bone mineral density response to zoledronic acid after hip fracture","volume":"29","author":"Magaziner","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2024021014264889600_jbmr2991-bib-0017","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1210\/jc.2008-2765","article-title":"Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density","volume":"94","author":"Eastell","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2024021014264889600_jbmr2991-bib-0018","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","article-title":"The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis","volume":"18","author":"Marcus","year":"2003","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Bone and Mineral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2991","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjbmr.2991","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/32\/1\/17\/56655102\/jbmr2991.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jbmr\/article-pdf\/32\/1\/17\/56655102\/jbmr2991.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T14:57:40Z","timestamp":1710341860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbmr\/article\/32\/1\/17-23\/7605923"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,9]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,9]]},"published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1002\/jbmr.2991","relation":{},"ISSN":["0884-0431","1523-4681"],"issn-type":[{"value":"0884-0431","type":"print"},{"value":"1523-4681","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,1,1]]},"published":{"date-parts":[[2016,9,9]]}}}